Baird analyst Michael Ulz reiterated an Outperform rating and $28.00 price target on Coherus Biosciences (NASDAQ: CHRS) after Symphony Health ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE